Progress made in HIV vaccine development

Nov 16, 2006

U.S. researchers report successfully testing two candidate vaccines that may eventually be used together to protect against HIV infection.

Dr. Barney Graham and colleagues from the National Institutes of Health Vaccine Research Center, the Fred Hutchinson Cancer Research Center in Seattle, and GenVec Inc. tested two possible HIV vaccines with the hope of producing an immune response in healthy, uninfected adults.

One candidate was a plasmid DNA-based vaccine expressing genes from three dominant HIV subtypes, and the second used recombinant adenovirus serotype 5 (rAd5) as a vector to deliver similar HIV strains.

Both vaccines were tested in healthy, uninfected adult volunteers. The DNA vaccine was found safe and well-tolerated. By the 12th week following immunization, 97.5 percent of vaccinees experienced positive CD4 T cell responses and 40 percent experienced positive CD8 T cell responses.

The recombinant vector vaccine was also well-tolerated but higher doses led to adverse events such as pain and fever. By the fourth week following immunization, 93.3 percent of vaccinees experienced positive CD4 T cell responses, and 60 percent experienced positive CD8 T cell responses.

The study is detailed in the Dec. 15 issue of The Journal of Infectious Diseases.

Copyright 2006 by United Press International

Explore further: Harm-reduction program optimizes HIV/AIDS prevention

add to favorites email to friend print save as pdf

Related Stories

Most detailed picture ever of key part of hepatitis C

Nov 28, 2013

Scientists at The Scripps Research Institute (TSRI) have determined the most detailed picture yet of a crucial part of the hepatitis C virus, which the virus uses to infect liver cells. The new data reveal ...

Recommended for you

Harm-reduction program optimizes HIV/AIDS prevention

31 minutes ago

(Medical Xpress)—New research from UC San Francisco and the San Francisco AIDS Foundation has found that clients participating in a harm-reduction substance use treatment program, the Stonewall Project, decrease their use ...

HIV+ women respond well to HPV vaccine

Apr 16, 2014

HIV-positive women respond well to a vaccine against the human papillomavirus (HPV), even when their immune system is struggling, according to newly published results of an international clinical trial. The study's findings ...

User comments : 0

More news stories

Scientists make critical end-stage liver discovery

(Medical Xpress)—A team of researchers in the University of Arizona's College of Pharmacy has discovered a molecular pathway that could be key to creating new therapeutics that would slow or even reverse ...

Solving cancer's secrets

Some fathers play ball with their sons. Or take them fishing. Chuck Perou's father took his son to his pathology lab to show him how a pathologist conducts tests and runs experiments. Perou, a nature junky ...

Harm-reduction program optimizes HIV/AIDS prevention

(Medical Xpress)—New research from UC San Francisco and the San Francisco AIDS Foundation has found that clients participating in a harm-reduction substance use treatment program, the Stonewall Project, decrease their use ...

Meth mouth menace

Something was up in Idaho. While visiting a friend in Athol, a small town north of Coeur d'Alene, Jennifer Towers, director of research affairs at the Tufts University School of Dental Medicine, noticed ...